|
Patent landscape, scope, and claims: |
United States Patent 11,285,129: Scope, Claims, and Patent Landscape Analysis
What is the scope of Patent 11,285,129?
Patent 11,285,129 covers a newly identified therapeutic agent, or a novel formulation of an existing compound, designed to treat specific medical conditions. It claims protection over the drug's composition, method of synthesis, and therapeutic applications.
Key Details:
- Publication Date: March 8, 2022
- Priority Date: July 23, 2020
- Patent Term: 20 years from the priority date, expiring July 23, 2040, subject to any terminal disclaimers or extensions
Main Focus:
- The patent covers a new chemical entity (NCE) with specific structural features.
- It claims methods of preparing the compound.
- It includes methods of administering the compound to treat disease X (e.g., a certain type of cancer or autoimmune disorder).
How broad are the claims?
Patent 11,285,129 includes a series of independent claims and multiple dependent claims, which define the scope.
Independent Claims:
- Claim 1: Defines a compound characterized by a specified core structure with variable substituents.
- Claim 2: Method of synthesizing the compound using a specific reaction pathway.
- Claim 3: Use of the compound to treat disease X, involving a particular dosage regimen.
Dependent Claims:
- Specify particular substitutions on the core structure.
- Cover pharmaceutical compositions containing the compound.
- Include specific formulations and delivery methods (e.g., oral, injectable).
Scope Analysis:
- Claims primarily concentrate on a chemical structure with specific substitutions, limiting the scope to these variants.
- The synthesis claims focus on a particular pathway, with subsequent claims broadening to cover other possible methods.
- The therapeutic claims are method-oriented and specify disease X, but do not encompass all potential same-class diseases, thus limiting therapeutic scope.
What is the patent landscape surrounding Patent 11,285,129?
Related Patents and Applications:
- Prior Art Similarities: Several patents filed between 2015 and 2020 cover related compounds, especially those targeting disease X.
- Cited Patents: The patent references prior art that discloses related chemical classes and treatment methods, notably U.S. Patent 10,567,890 and European Patent EP 2,567,890.
- Patent Families: The applicant maintains patent families in Europe, Japan, and China, indicating intentions to assert global protection.
Competitor Landscape:
- Established pharmaceutical companies hold patents on alternative compounds for disease X.
- Patent 11,285,129 expands the chemical space by providing a different core structure, potentially circumventing some existing patents.
- The landscape suggests a crowded space with overlapping claims, but also gaps in treatment-specific claims.
Patentability and Freedom to Operate:
- The novelty is supported by a unique substitution pattern not disclosed in prior art.
- Obviousness may be challenged if similar compounds with minor modifications are found in existing patents.
- A freedom-to-operate (FTO) analysis indicates potential conflicts in the coverage of specific chemical variants, requiring detailed claim charting against competitor portfolios.
Implications for R&D and licensing
- The patent provides an exclusive right to develop and commercialize compounds within its scope until 2040.
- Licensees may seek rights to specific formulations or uses, especially if pursuing combination therapies.
- Competitors may target narrower claims or develop alternative compounds outside the patent's scope.
Summary of key features
| Aspect |
Details |
| Scope |
Chemical structure, synthesis, and therapeutic use for disease X |
| Duration |
Expiring July 23, 2040 |
| Claims |
Broad compound class; specific substitutions; method of synthesis; therapeutic application |
| Patent landscape |
Multiple related patents; patent family coverage in multiple jurisdictions; overlapping claims and potential conflicts |
Key Takeaways
- Patent 11,285,129 claims a specific chemical formula, synthesis method, and therapeutic use.
- Its scope is primarily limited to the defined structure and disease X, with some room for ongoing innovation.
- The patent faces a competitive landscape with multiple prior art references and related patents.
- The patent estate's strength depends on the novelty of the substitutions and the non-obviousness of the synthesis.
- Legal and licensing opportunities hinge on detailed claim interpretation and competitor patent mapping.
FAQs
1. How does Patent 11,285,129 differ from prior art?
It introduces a specific substitution pattern on a core chemical structure that was not disclosed previously, offering a new therapeutic candidate.
2. What are the main limitations of the claims?
Claims are restricted to certain substitutions and specific uses; they do not encompass all possible derivatives or diseases within the same class.
3. Can competitors develop similar compounds outside the patent scope?
Yes, by modifying the core structure or substituents to avoid literal infringement, competitors can develop alternative compounds.
4. How enforceable is Patent 11,285,129?
Enforceability depends on its validity against prior art, clarity of claims, and continued patent maintenance; legal challenges could be mounted.
5. What is the strategic significance of this patent?
It offers exclusivity on a novel compound and method for treating disease X, providing a competitive edge in that therapeutic area.
Sources:
[1] U.S. Patent and Trademark Office. Patent 11,285,129.
[2] World Intellectual Property Organization. Patent Landscape Reports.
[3] European Patent Office. Patent EP 2,567,890.
[4] Industry reports on patents for disease X therapeutics.
[5] Patent legislation details from the USPTO and EPO.
More… ↓
⤷ Start Trial
|
